Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level650 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07108855 | Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection(BRIGHT) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02205047 | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma(INNOVATION) | completed | Phase 2 | 172 | European Organisation for Research and Treatment of Cancer - EORTC |
| 13 |
| Jul 31, 2025 |
| clinicaltrials |
| NCT07085273 | Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer | not yet recruiting | Phase 2 | 33 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Artiva Biotherapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT06732856 | A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer(NEO-CLAUD) | recruiting | Phase 1 / Phase 2 | 57 | Asan Medical CenterOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness(DANTE) | active not recruiting | Phase 2 | 677 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 25, 2025 | clinicaltrials |
| NCT03636893 | Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer | completed | Phase 2 | 74 | Ruijin HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06427252 | The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04592211 | Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer | recruiting | Phase 1 / Phase 2 | 71 | Yonsei UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05894824 | T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 58 | Yonsei UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07050524 | Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial | not yet recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06895447 | Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07045805 | Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer | not yet recruiting | Phase 2 | 66 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT04963088 | Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)(TALENT) | completed | Phase 1 / Phase 2 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT02078700 | Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. | completed | Phase 2 | 40 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06812403 | Combination COMBO Endoscopy Oropharyngeal Airway With High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients | completed | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06728657 | Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma(TORCH-G) | suspended | Phase 2 | 68 | Fudan UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06766305 | QL1706 Combined With SOX Used in Theperioperative Treatment | recruiting | Phase 1 / Phase 2 | 54 | Xiangdong ChengOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07018063 | Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer(YOUNG-NEOS) | not yet recruiting | Phase 2 | 35 | zhoujingOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial(PLATFORM) | active not recruiting | Phase 2 | 494 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | terminated | Phase 1 / Phase 2 | 28 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Jun 8, 2025 | clinicaltrials |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | active not recruiting | Phase 1 / Phase 2 | 192 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT06157996 | Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore | recruiting | Phase 2 | 92 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06804876 | COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients | completed | Phase 2 | 107 | Zhejiang UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06980389 | Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC) | not yet recruiting | Phase 2 | 176 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT05311176 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)(nextHERIZON) | terminated | Phase 2 | 7 | Imugene LimitedINDUSTRY | 2 | May 11, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06742411 | XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC | recruiting | Phase 1 / Phase 2 | 57 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT06957977 | A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer | not yet recruiting | Phase 2 | 42 | Zhongguang Luo, MDOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06759233 | Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer | not yet recruiting | Phase 2 | 15 | Zhongguang Luo, MDOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06942767 | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | not yet recruiting | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06942663 | Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer(JAGC1) | not yet recruiting | Phase 2 | 228 | Nizhny Novgorod Regional Clinical Oncology CenterOTHER_GOV | 0 | Apr 24, 2025 | clinicaltrials |
| NCT02142322 | Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer | completed | Phase 2 | 52 | Seoul National University HospitalOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03609359 | Lenvatinib and Pembrolizumab Simultaneous Combination Study(Lenva+Pembro) | completed | Phase 2 | 29 | National Cancer Center Hospital EastOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06685887 | A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis | recruiting | Phase 2 | 34 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03064490 | Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)(PROCEED) | completed | Phase 2 | 35 | Duke UniversityOTHER | 1 | Apr 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2025source: clinicaltrials